| Theme | Revival of renal osteodystrophy -- new treatment targeting bone | |
|---|---|---|
| Title | Lanthanum carbonate : powerful phosphate binder | |
| Publish Date | 2016/12 | |
| Author | Yusuke Tanaka | Division of Nephrology, Department of Internal Medicine, Wakayama Medical University |
| Author | Keiko Iseki | Division of Nephrology, Department of Internal Medicine, Wakayama Medical University |
| Author | Satoko Kunimoto | Division of Nephrology, Department of Internal Medicine, Wakayama Medical University |
| Author | Mari Moribata | Division of Nephrology, Department of Internal Medicine, Wakayama Medical University |
| Author | Takashi Shigematsu | Division of Nephrology, Department of Internal Medicine, Wakayama Medical University |
| [ Summary ] | Lanthanum carbonate was approved in Japan as a powerful non-calcemic phosphate binder in 2009. This compound can achieve and maintain serum phosphate levels within guideline levels while providing lower tablet burden levels. A number of several studies have reported that lanthanum carbonate inhibits progression of vascular calcification. Other studies have also reported serum FGF23 reduction with lanthanum treatment. Furthermore, these effects may improve patients' longterm outcomes. There is some concern that lanthanum carbonate may accumulate in the body and it may exhibit toxicity. Adverse events such as those related to aluminum containing phosphate binders have not been reported over the 8 years it has been prescribed in Japan. However, gastrointestinal deposition of lanthanum has been reported recently. We must keep mind lanthanum's adverse effects in the future. | |